The impact of escalating regulatory requirements on the conduct of clinical research

By Gordon Bg   Kessinger A   Mann Sl   Prentice Ed  

Cytotherapy, Vol. 5, Iss. 4, 2003-08 ,pp. : 309-313

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Good manufacturing practice-grade production of unrestricted somatic stem cell from fresh cord blood

By Aktas Murat   Buchheiser Anja   Houben Amelie   Reimann Verena   Radke Teja   Jeltsch Kathrin   Maier Patrick   Zeller W. Jens   Kogler Gesine  

Cytotherapy, Vol. 12, Iss. 3, 2010-04 ,pp. : 338-348

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Regulatory issues in cellular therapies

By Sharp Jg  

Cytotherapy, Vol. 5, Iss. 4, 2003-08 ,pp. : 277-278

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant

By Sili Uluhan   Leen Ann M.   Vera Juan F.   Gee Adrian P.   Huls Helen   Heslop Helen E.   Bollard Catherine M.   Rooney Cliona M.  

Cytotherapy, Vol. 14, Iss. 1, 2012-01 ,pp. : 7-11

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy

By Tam Yk   Martinson Ja   Doligosa K   Klingemann H-g  

Cytotherapy, Vol. 5, Iss. 3, 2003-01 ,pp. : 259-272

Ashgate Publishing Ltd

Access to resources Recommend Favorite